A randomised phase II study of pemetrexed versus pemetrexed + erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer

导出原文传递

翻译打印收藏纠错

作者： Dittrich,C. ^[1] ; Papai-Szekely,Z. ^[2] ; Vinolas,N. ^[3] ; Sederholm,C. ^[4] ; Hartmann,J.T. ^[5] ; Behringer,D. ^[6] ; Kazeem,G. ^[7] ; Desaiah,D. ^[8] ; Leschinger,M.I. ^[9] ; VonPawel,J. ^[10]

作者单位： Hospital Clinic i Provincial, Barcelona, Spain ^[1] Eli Lilly Corporate Center, Indianapolis, United States ^[2] Clinic of Hematology and Oncology, Bochum, Germany ^[3] St. George Hospital of Fejér County, Szekesfehervar, Hungary ^[4] Asklepios Hospital München-Gauting, Gauting, Germany ^[5] Eli Lilly UK, Erl Wood Manor, Windlesham, Surrey, United Kingdom ^[6] University Hospital, Link?ping, Sweden ^[7] Lilly Deutschland GmbH, Bad Homburg, Germany ^[8] Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LBC Translational ^[9] Department of Internal Medicine II-Hematology and Medical Oncology, Kiel, Germany ^[10]

关键词 Erlotinib Non-small cell lung cancer Non-squamous Pemetrexed Second-line therapy

发布时间 2018-08-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交